Daxor Quote - DXR

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

8.1001

Bid

7.75

Ask

8.10

Volume

2,533

8.00 Day's Range 8.1001

6.55 52 Week Range 10.00

Market Cap

39.204M

Previous Close

7.75

Open

8.01

Last Trade

8.1

Last Trade Time

13:17:20

Financial Volume

US$ 20,427

VWAP

8.0643

Average Volume (3m)

6,440

Shares Outstanding

4,840,000

Dividend Yield

PE Ratio

187.26

Earnings Per Share (EPS)

0.06

Revenue

163k

Net Profit

281k

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and compos... Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. Show more

Sector

Surgical,med Instr,apparatus

Industry

Misc Health & Allied Svc,nec

Website

www.daxor.com

Headquarters

Oak Ridge, New Jersey, USA

Founded

2010

Daxor Corporation is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DXR. The last closing price for Daxor was US$7.75. Over the last year, Daxor shares have traded in a share price range of US$ 6.55 to US$ 10.00.

Daxor currently has 4,840,000 shares outstanding. The market capitalization of Daxor is US$37.51 million. Daxor has a price to earnings ratio (PE ratio) of 187.26.

Form 4 - Statement of changes in beneficial ownership of securities

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results...

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.6501	8.72617449664	7.45	8.1001	7.1503	4909	7.86437003	CS
4	0.8501	11.7255172414	7.25	8.1001	6.55	7656	7.47894251	CS
12	9.99999999998E-5	0.00123456790123	8.1	8.88	6.55	6440	7.75166433	CS
26	-1.3799	-14.555907173	9.48	10	6.55	11884	8.79824498	CS
52	0.1201	1.50501253133	7.98	10	6.55	7272	8.83902383	CS
156	-2.9099	-26.429609446	11.01	14.55	6.55	5316	9.61726653	CS
260	-2.8699	-26.161349134	10.97	14.55	6.55	5159	9.62228122	CS

DXR - Frequently Asked Questions (FAQ)

What is the current Daxor share price?

The current share price of Daxor is US$ 8.1001

How many Daxor shares are in issue?

Daxor has 4,840,000 shares in issue

What is the market cap of Daxor?

The market capitalisation of Daxor is USD 37.51M

What is the 1 year trading range for Daxor share price?

Daxor has traded in the range of US$ 6.55 to US$ 10.00 during the past year

What is the PE ratio of Daxor?

The price to earnings ratio of Daxor is 187.26

What is the cash to sales ratio of Daxor?

The cash to sales ratio of Daxor is 322.85

What is the reporting currency for Daxor?

Daxor reports financial results in USD

What is the latest annual turnover for Daxor?

The latest annual turnover of Daxor is USD 163k

What is the latest annual profit for Daxor?

The latest annual profit of Daxor is USD 281k

What is the registered address of Daxor?

The registered address for Daxor is 107 MECO LANE, OAK RIDGE, NEW JERSEY, 37830

What is the Daxor website address?

The website address for Daxor is www.daxor.com

Which industry sector does Daxor operate in?

Daxor operates in the MISC HEALTH & ALLIED SVC,NEC sector

Symbol	Price	Vol.
RAYRaytech Holding Ltd	US$ 1.74 (100.00%)	91.61M
SYRSSyros Pharmaceuticals Inc	US$ 0.1672 (82.53%)	658.73M
TSVT2seventy bio Inc	US$ 4.945 (76.61%)	29.55M
TNONTenon Medical Inc	US$ 1.8901 (51.21%)	33.08M
HSAIHesai Group	US$ 23.675 (47.88%)	23.47M
WCTWellchange Holdings Company Limited	US$ 0.7248 (-71.12%)	29.27M
ARVNArvinas Inc	US$ 8.59 (-51.08%)	13.75M
LZMHLZ Technology Holdings Ltd	US$ 8.34 (-46.74%)	517.87k
SPGCSacks Parente Golf Inc	US$ 0.1034 (-35.42%)	31.87M
MDCXMedicus Pharma Ltd	US$ 2.5295 (-25.60%)	93.44k
SYRSSyros Pharmaceuticals Inc	US$ 0.1671 (82.42%)	658.75M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0389 (16.12%)	388.47M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8.10 (9.76%)	255.7M
NVDANVIDIA Corporation	US$ 110.31 (3.11%)	254.15M
CUTRCutera Inc	US$ 0.1089 (-15.25%)	209.74M

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Daxor Corporation (DXR) Share Price

Daxor Corporation (DXR)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Daxor Corporation

Ask ADVFN Intelligence (AI)

DXR Latest News

Form 4 - Statement of changes in beneficial ownership of securities

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Form N-CSR - Certified Shareholder Report

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Form 4 - Statement of changes in beneficial ownership of securities

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Form N-CSR - Certified Shareholder Report

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

DXR - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free